3629 results for «333»

Filter By

3629 results

Advanced TAVI: techniques, timing, and problem-solving

12 Sep 2025 – From PCR Rio Valves 2025

Advance your knowledge in TAVI with this session addressing sophisticated techniques, procedural timing, and problem-solving in complex cases. Explore TAVI applications in rare quadricuspid valve anatomy with pure aortic insufficiency, strategic decision-making between TAVI and PCI, and innovative solutions for managing aortic stenosis in patients with...

Tailored transfemoral TAVI in complex anatomies - LIVE Case

11 Sep 2025 – From PCR Rio Valves 2025

Supported by an unrestricted educational grant from Medtronic

An 89-year-old male with hypertension, dyslipidemia, current smoking, stage III kidney disease, and a history of diagonal PCI in 2010 presented with severe symptomatic aortic stenosis and a small annulus (410 mm²), with RBBB on ECG.

Via bilateral femoral access,...

Tailored transfemoral TAVI in complex anatomies - LIVE Case

The role of mitral TEER in advanced heart failure

11 Sep 2025 – From PCR Rio Valves 2025

This session delves into the role of mitral transcatheter edge-to-edge repair (TEER) in advanced heart failure patients. Understand the indications for mitral TEER in severe left ventricular dysfunction, prognostic challenges in heart failure with severe mitral regurgitation, and review therapeutic alternatives including the pathway from TEER...

The role of mitral TEER in advanced heart failure

Redo TAVI

12 Sep 2025 – From PCR Rio Valves 2025

This session focuses on the challenges and strategies of redo TAVI, from careful planning to valve selection and tailored procedural approaches. Learn how to manage different valve platforms, optimise outcomes in valve-in-valve scenarios, and prevent complications such as coronary obstruction through real case discussions.

Redo TAVI

Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial

27 Dec 2020

The MAGSTEMI trial showed larger endothelium-independent vasodilatation with magnesium-based bioresorbable scaffolds (MgBRS) than with sirolimus-eluting stents (SES). However, restenosis was more frequent with MgBRS. The aims of this study were to compare the healing pattern between MgBRS and SES and to describe the main causes of...

Authors :

J. Gomez-Lara, L. Ortega-Paz, S. Brugaletta, J. Cuesta, S. Romaní, A. Serra, P. Salinas, B. García del Blanco, J. Goicolea, R. Hernandez-Antolín, P. Antuña, R. Romaguera, A. Regueiro, F. Rivero, Àngel Cequier, F. Alfonso, J.Antoni Gómez-Hospital, M. Sabaté
EuroIntervention: BRS versus permanent sirolimus-eluting stents in patients with STEMI: vascular healing outcomes from the MAGSTEMI trial

Elixir Medical completes enrollment in BIOADAPTOR randomized controlled trial of Dynamx Coronary Bioadaptor System

15 Feb 2022

Dynamx bioadaptor restores rotational motion and vessel stress reduction in new study

02 Jun 2022

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

M. Pighi

Author

Michele Pighi
Bioprosthetic valve fracture in ViV-TAVR
Didn’t find what you were looking for?